Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H32O2S |
Molecular Weight | 288.489 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCCCCCCCCCCCCSCC(O)=O
InChI
InChIKey=IPBCWPPBAWQYOO-UHFFFAOYSA-N
InChI=1S/C16H32O2S/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-19-15-16(17)18/h2-15H2,1H3,(H,17,18)
Tetradecylthioacetic acid (TTA) is a hypolipidemic antioxidant with immunomodulating properties involving activation of peroxisome proliferator-activated receptors (PPARs). TTA exerts both hypolipidemic and anti-inflammatory effects in psoriasis patients - TTA can be of therapeutic benefit for a subgroup of psoriatic patients. TTA may improve myocardial function in heart failure, potentially involving its ability to decrease the availability of free fatty acids in plasma and increase the myocardial proportion of n-3 polyunsaturated fatty acids. TTA attenuates dyslipidemia in patients with type 2 diabetes mellitus. These effects may occur through mechanisms involving PPAR-alpha and PPAR-delta activation, resulting in increased mitochondrial fatty acid oxidation.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL239 |
|||
Target ID: CHEMBL3979 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19267708 |
|||
Target ID: CHEMBL235 Sources: https://www.ncbi.nlm.nih.gov/pubmed/19267708 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
11 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
1000 mg single, oral dose: 1000 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
11.5 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
600 mg single, oral dose: 600 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
14 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
1000 mg 1 times / day multiple, oral dose: 1000 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
2.9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
4 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
200 mg 1 times / day multiple, oral dose: 200 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
9 mg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/18427285 |
600 mg 1 times / day multiple, oral dose: 600 mg route of administration: Oral experiment type: MULTIPLE co-administered: |
TETRADECYLTHIOACETIC ACID serum | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
PubMed
Title | Date | PubMed |
---|---|---|
Antiproliferative effects of a non-beta-oxidizable fatty acid, tetradecylthioacetic acid, in native human acute myelogenous leukemia blast cultures. | 2002 Nov |
|
Nuclear import of factors involved in signaling is inhibited in C3H/10T1/2 cells treated with tetradecylthioacetic acid. | 2002 Oct |
|
PPARalpha activators and fasting induce the expression of adipose differentiation-related protein in liver. | 2006 May |
|
Dose-dependent coronary artery intimal thickening after local delivery of the anti-oxidant tetradecylthioacetic acid from stents. | 2007 Nov |
|
Platelet activating factor stimulates arachidonic acid release in differentiated keratinocytes via arachidonyl non-selective phospholipase A2. | 2010 Apr |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00605787
1000mg capsules once daily for 28 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19267708
In cultured human skeletal muscle cells (myotubes), 24-h preincubation with 100 uM of tetradecylthioacetic acid significantly enhanced production of [1-14C]CO2 from oxidation of [1-14C]oleic acid in a dose-responsive manner.
Name | Type | Language | ||
---|---|---|---|---|
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
2921-20-2
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
DTXSID0040759
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
114924
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
7ZU5I25S2O
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY | |||
|
TETRADECYLTHIOACETIC ACID
Created by
admin on Fri Dec 15 17:57:06 GMT 2023 , Edited by admin on Fri Dec 15 17:57:06 GMT 2023
|
PRIMARY |
ACTIVE MOIETY